Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-GSK2849330 PET biodistribution study in HER3-positive advanced solid tumors
NL-OMON44283Active, not recruiting
- Sponsor
- GSK
- Start
- Mar 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of GSK2849330 in Nonhematologic neoplasms, sponsored by GSK. Primary endpoints: Quantitative PET-CT biodistribution parameters and SUV and region of interest volume. Started Mar 2015; status: active, not recruiting.
02
Drugs
GSK2849330
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON44283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44283.